Bavarian Nordic to start phase III with Covid-19 booster in June

Bavarian Nordic is aiming to demonstrate that its Covid-19 booster vaccine candidate ABNCov2 is just as good as Pfizer’s.

Photo: Bavarian Nordic / PR

Danish biotech firm Bavarian Nordic will begin a phase III trial of its Covid-19 vaccine in June, 2022, according to database Clinical Trials.

To test the company’s candidate, ABNCov2, Bavarian will recruit patients who have already received Comirnaty (Pfizer/Biontech), Spikevax (Moderna), Vaxzevria (Astrazeneca), Janssen Covid-19 vaccine (Johnson & Johnson) or other approved vaccines in the EU and US, according to the registration.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs